JT3 (@Joshthe3rd_) header
JT3 (@Joshthe3rd_) profile picture

JT3

@Joshthe3rd_

Always learning from mistakes and always adapting. https://nitter.cf/t.co/ddEatJXh6c (Charts + Notes posted here as well)

 Antarctica
Joined February 2021
  • Tweets3.2K
  • Following264
  • Followers1K
938Media
Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)Photo by JT3 (@Joshthe3rd_)
*Updated* 500M+ Biotech Public Offerings 2024-2026 (6/20/26) added (CYTK) I will create a new one at YE. $XBI
Image from JT3 (@Joshthe3rd_)
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Jun 20
1/ 500M+ biotech offerings 2024-2026 $XBI ABVX - 743M PO at 64.00 (2025) INSM - 750M PO at 96.00 (2025) PCVX - 1.3B PO at 103.00 (2024) PCVX - 632M PO at 50.00 (51.00) VKTX - 550M PO at 85.00 (2024) IONS - 500M PO at 43.50 (2024) RVMD - 750M PO at 46.00 (2024) RVMD - 1.65B PO
3
5
2
43
37,397
$MTRI should continue to bounce/rally off the 200MA daily.
Image from JT3 (@Joshthe3rd_)
1
133
probably will become the next SYRE style runner over the next few years
68
$LGVN substack.com/@jt312/note/c-3…
116
We are always only 2 affairs away from crashing the stock market.
Image from JT3 (@Joshthe3rd_)
2
262
JT3 retweeted
bnuoH (@lcbnuoH) profile picture
bnuoH@lcbnuoH13h
Biotech CEOs are usually so poor that they can only have regulatory Affairs.
17
48
6
545
21,517
$LGVN cash is low. Just need them to update their "cash conservation measures" and seee some signs of bottoming then they are good to go for strat alt. As long as they don't dilute the piss out of it to keep the low float it could spike like NXTC did on a merger announcement.
2
4
929
Interesting trend 🤔 Especially when you time stamp these and know the float at the time. Would prefer some better TA signs of bottoming though.
Image from JT3 (@Joshthe3rd_)
135
substack.com/@jt312/note/c-3…
1
507
$CNSP would prefer to snag shares at the private placement price at 2.30. Volume is non-existent though.
Image from JT3 (@Joshthe3rd_)
275
$ELOX 📚🕰️
Image from JT3 (@Joshthe3rd_)
1
357
This one is a forgotten up-list biospace.com/press-releases/…
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to...

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to...

biospace.com
186
$TSHA 🤔
Image from JT3 (@Joshthe3rd_)
250
$TCRX cash through end of 2027. Preclin data for in-vivo tumor asset in q1 2027. If they can't raise then will be forced to strat alt. We wait for now.
285
$INO
8
409
$XBI despite the carnage still maintaining a decent trend on the daily. Should retest the 200MA daily though.
Image from JT3 (@Joshthe3rd_)
1
2
414
Days of the old XBI are behind us. Now the index has higher quality commercial/p2/3 names flush with cash. We will have dips, but willing to bet they will be less exaggerated then the ones in the past. Though high risk clinical biotechs 100% got nuked and look like the old XBI.
198
$DTIL 🥳
Image from JT3 (@Joshthe3rd_)
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Oct 30
Replying to @Joshthe3rd_
This can be a sign of a bigger move to the upside to follow. And considering both seemed to avoid the liquidations knife pretty well + PRME gaining momentum, I like the r/r. I did work on DTIL, but am catching up on my DD for edit.
2
323
ah thats what I missed $YARW did the first initial merger offering at 7.06
Image from JT3 (@Joshthe3rd_)
223
$KRRO kind of reminds me of similarities to $RGLS.
JT3 (@Joshthe3rd_) profile pictureJT3@Joshthe3rd_Jul 16
Been thinking about all the early stage ADC biotech M&A that has happened over the last few years. I wonder if early stage RNA editing bios are next.
3
370
$VRDN 008 data in Q4
Image from JT3 (@Joshthe3rd_)
1
2
541
$XFOR $KRRO catalysts a long ways out but are in tight weekly ranges.
Image from JT3 (@Joshthe3rd_)
Image from JT3 (@Joshthe3rd_)
332
Load more